Amneal Pharmaceuticals, Inc.
AMRX
$11.90
-$0.29-2.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -89.43% | 83.82% | 139.24% | -19,823.72% | -102.60% |
| Total Depreciation and Amortization | -10.05% | -0.08% | -9.03% | 12.16% | 6.10% |
| Total Amortization of Deferred Charges | -26.84% | 0.94% | -74.23% | 229.29% | 7.77% |
| Total Other Non-Cash Items | 264.87% | -14.73% | -0.33% | 7.98% | 17.60% |
| Change in Net Operating Assets | -44.52% | 67.00% | -586.75% | -48.90% | 175.41% |
| Cash from Operations | 41.32% | 1,031.47% | -93.73% | -16.71% | 257.50% |
| Capital Expenditure | 43.21% | -87.66% | 37.13% | -31.28% | -59.87% |
| Sale of Property, Plant, and Equipment | -100.00% | 63.17% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -100.00% |
| Other Investing Activities | -723.78% | 78.57% | -600.00% | 83.33% | -380.00% |
| Cash from Investing | 15.38% | -49.16% | -10.83% | 22.47% | -220.37% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -16,328.53% | 93.40% | -324.11% | 36.32% | -223.05% |
| Issuance of Common Stock | -4.67% | 892.75% | -54.30% | -75.53% | 72.35% |
| Repurchase of Common Stock | 31.75% | 99.13% | -5,491.47% | -99.48% | -22.01% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -226.99% | -39,069.12% | 98.75% | 2.27% | 32.94% |
| Cash from Financing | 242.59% | -6.44% | 36.01% | 33.72% | -163.20% |
| Foreign Exchange rate Adjustments | -126.06% | 34.68% | 36.49% | -10,671.43% | 106.93% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 912.80% | 130.54% | -224.83% | 39.52% | 1,539.75% |